Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
AVR Catalyst Timeline
Dated clinical, regulatory and corporate events for Anteris Technologies Global Corp.
Past FDA Catalysts and PDUFA Decisions
How AVR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
Anteris Technologies Global Corp. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every AVR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| DurAVR THV | severe aortic stenosis | 2025-11-17 | single digit mean gradients; large effective orifice areas (EOAs); no moderate or severe paravalvular leaks; no valve related mortality; 97% freedom from moderate or severe prosthesis-patient mismatchRead More | Anteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves MINNEAPOLIS, United States and BRISBANE, Australia 17 November 2025: Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| L1 Capital Pty Ltd10% Owner | Buy | 272,695 6,358,271 held | $7.18 | 10/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AVR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.5 % | 26.62 M | 3.43 M |
Ownership Trends
AVR Short Interest
Shares sold short, counted twice a month.
Options Data
AVR Option Volume & Put-Call Ratio
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How AVR ranks across every disease it competes in
AVR News
Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients
Anteris Technologies announced that Dr. Rishi Puri will present one-year outcomes for the DurAVR Transcatheter Heart Valve at PCR London Valves. The study includes data from 100 patients with severe aortic stenosis. The DurAVR THV is designed to replicate normal aortic blood flow using advanced biomimetic technology.
Read more →Anteris Technologies Announces Results for the Third Quarter of 2026
Anteris Technologies reported positive developments in Q3 2026, including progress in the PARADIGM Trial with expanded enrollment across multiple countries. The trial received regulatory approvals in Germany and Australia, facilitating its geographic reach. Additionally, the company has increased production capacity with a new facility and appointed a new CFO to support its commercialization efforts.
Read more →Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026
Anteris Technologies reported positive 30-day outcomes for the Medium-size DurAVR THV in patients with severe aortic stenosis. The results, presented at the TCT Conference, indicated no valve-related mortality and favorable hemodynamic profiles. The ongoing PARADIGM trial aims to further evaluate the safety and effectiveness of DurAVR THV compared to existing TAVRs.
Read more →Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026
Anteris Technologies announced that Dr. Azeem Latib will present 30-day clinical outcomes for the medium-size DurAVR THV at TCT 2026. The presentation will focus on patients with severe aortic stenosis from the EMBARK study, which has treated over 130 patients since 2021. The conference will take place in San Diego from October 31 to November 3, 2026.
Read more →Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance
Anteris Technologies announced regulatory clearance from Germany's BfArM for its DurAVR® Transcatheter Heart Valve in the PARADIGM Trial. This allows patient recruitment at leading German centers, enhancing the trial's European footprint. The trial aims to evaluate the safety and effectiveness of the DurAVR® THV against existing TAVRs.
Read more →Anteris to Present at September Healthcare Investor Conferences
Anteris Technologies Global Corp. will present at three major healthcare conferences in September 2026. CEO Wayne Paterson will discuss the company's innovative medical devices, including the DurAVR Transcatheter Heart Valve, designed to treat aortic stenosis. The conferences include the Cantor Global Healthcare Conference, Wells Fargo Healthcare Conference, and Morgan Stanley Healthcare Conference.
Read more →Anteris Technologies Announces Results for the Second Quarter of 2026
Anteris Technologies reported positive Q2 2026 results, securing U.S. Medicare reimbursement for the PARADIGM Trial. The company initiated recruitment in the U.S. and expanded the trial to Denmark and the Netherlands. Additionally, new board members were appointed to strengthen governance as the DurAVR® THV moves toward commercialization.
Read more →Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
Anteris Technologies Global Corp. has secured full regulatory clearance from the French National Agency for Medicines and Health Products Safety for its DurAVR Transcatheter Heart Valve in the PARADIGM clinical trial. This authorization enables the company to begin patient recruitment in France, marking a key milestone in its global clinical strategy. The trial aims to evaluate the safety and efficacy of the DurAVR valve compared to available transcatheter aortic valve replacements, with an enrollment goal of approximately 1,000 patients. Anteris is committed to advancing treatment options for severe calcific aortic stenosis.
Read more →Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
Anteris Technologies has appointed Susan Knight and Stephen Denaro to its Board of Directors. Knight brings extensive experience from her previous roles, while Denaro returns with deep knowledge of the company. These appointments aim to strengthen governance and support the company's clinical and commercial objectives, particularly for the DurAVR® THV.
Read more →Anteris Announces Results for the First Quarter of 2026
Anteris Technologies reported its Q1 2026 financial results, highlighting strong execution in the PARADIGM Trial with ongoing patient enrollment in Europe and the U.S. The company noted that recent CMS coverage will support recruitment efforts. However, they reported significant cash outflows due to clinical and regulatory expenses.
Read more →Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial
Anteris Technologies has announced the successful enrollment and treatment of the first U.S. patients in its global pivotal PARADIGM Trial for the DurAVR® Transcatheter Heart Valve. This trial aims to evaluate the safety and effectiveness of their innovative heart valve compared to existing transcatheter aortic valve replacements. Dr. Azeem Latib has reported promising early experiences with the new valve, highlighting the trial's importance in advancing heart care. The study is aimed at enrolling approximately 1000 patients to assess various health outcomes over the course of the trial.
Read more →Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial
Anteris Technologies has announced that it secured U.S. Medicare reimbursement eligibility for its PARADIGM Trial, which will evaluate the DurAVR® Transcatheter Heart Valve against commercially available TAVRs. This milestone is expected to enhance U.S. site activation and operational momentum. The trial aims to enroll around 1000 patients to assess the safety and effectiveness of the DurAVR® THV.
Read more →Anteris Reports 2025 Financial Results and Provides Corporate Update
Anteris Technologies reported its 2025 financial results, highlighting advancements in its DurAVR product and the initiation of the PARADIGM Trial. The company aims to strengthen its position in the structural heart market while managing significant cash outflows related to clinical and regulatory needs. CEO Wayne Paterson emphasized the importance of clinical evidence and sustainable value creation.
Read more →Results for announcement to the market Name of entity: Anteris Technologies Global Corp. ("ATGC") ARBN: 677 960 235 Reporting period: For the year ended 31 December 2025 The attached Form 10-K Annual Report for the year
Anteris Technologies Global Corp. has released its Form 10-K Annual Report for the year ended December 31, 2025. The report indicates a significant decline in revenue and an increase in net losses compared to the prior year. Despite the financial challenges, Anteris is notable for its innovative DurAVR Transcatheter Heart Valve, designed to address aortic stenosis. The company continues to report on its developments and financial maneuvers in compliance with respect to ASX listing rules.
Read more →Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays
Anteris Technologies Global Corp. will present at the TD Cowen and Barclays Healthcare Conferences. CEO Wayne Paterson will discuss the company's innovative heart devices, including the DurAVR® Transcatheter Heart Valve, designed to treat aortic stenosis. The webcasts of the presentations will be available on the company's website.
Read more →Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises
Anteris Technologies has secured a $90 million strategic investment from Medtronic, contributing to a total of $320 million raised. This funding will facilitate the global pivotal PARADIGM trial for the DurAVR® Transcatheter Heart Valve (THV). Both companies aim to enhance the TAVR market through innovation and improved patient outcomes.
Read more →Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock
Anteris Technologies Global Corp. has successfully closed a public offering of 40 million shares at $5.75 each, raising approximately $230 million. Additionally, the company completed a private placement of over 15 million shares to Medtronic, totaling around $320 million in gross proceeds. The funds will be used to advance their clinical strategy, particularly for the DurAVR® Transcatheter Heart Valve trial.
Read more →Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic
Anteris Technologies Global Corp. has announced a proposed public offering of $200 million in common stock, with an additional $30 million option for underwriters. The company will also engage in a private placement with Medtronic for up to $90 million. Proceeds will support the DurAVR®THV global pivotal trial and expand manufacturing capabilities.
Read more →Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering
Anteris Technologies Global Corp. has announced a public offering of 34,782,609 shares at $5.75 each, aiming to raise approximately $200 million. The offering is set to close on January 22, 2026, and will support the company's clinical strategy, including the DurAVR®THV global pivotal trial. Additionally, a private placement with Medtronic for up to $90 million is planned, contingent on the completion of the offering.
Read more →Anteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves
Anteris Technologies Global Corp. presented promising 30-day clinical outcomes from a cohort of 100 patients with severe aortic stenosis treated with the DurAVR THV valve at the PCR London Valves conference. The data revealed single-digit mean gradients and effective orifice areas, alongside no significant complications like valve-related mortality or paravalvular leaks. The results also indicated a remarkable 97% freedom from moderate or severe prosthesis-patient mismatch, offering optimism for the valve’s performance in small aortic annuli patients. The findings are expected to bolster confidence as the company progresses towards larger trials and commercialization efforts.
Read more →